Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 17.48%-271.83K | 49.31%-147.09K | -21.86%-290.55K | -84.73%-1.12M | -55.75%-260.25K | -170.22%-329.43K | -57.91%-290.16K | -79.80%-238.42K | 34.94%-605.36K | -11.10%-167.09K |
| Net income from continuing operations | 2.07%-480.22K | -1.27%-476.84K | -121.91%-1.03M | -26.02%-2.65M | -159.66%-1.22M | 30.82%-490.38K | -2.57%-470.84K | -0.17%-462.28K | -1.20%-2.1M | 5.87%-471.27K |
| Operating gains losses | ---- | ---- | ---- | --10.12K | --0 | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Asset impairment expenditure | ---- | ---- | ---- | --624.5K | ---- | ---- | ---- | ---- | --0 | ---- |
| Unrealized gains and losses of investment securities | --0 | --0 | --0 | -492.70%-18.29K | 542,000.00%5.42K | -471.19%-3.09K | -530.54%-16.46K | ---4.16K | -82.00%4.66K | --1 |
| Remuneration paid in stock | --0 | --0 | --580K | --0 | --0 | --0 | --0 | --0 | 33.75%269.5K | --0 |
| Other non cashItems | 4.50%267.36K | 6.73%267.28K | -2.27%242.13K | 5.38%1.02M | 6.19%261.4K | 5.23%255.85K | 4.85%250.42K | 5.23%247.75K | 6.50%963.57K | 4.13%246.16K |
| Change In working capital | 42.14%-58.97K | 217.23%62.46K | -339.98%-86.82K | -139.91%-102.8K | 24.33%72.14K | -238.71%-101.93K | -263.39%-53.28K | -121.11%-19.73K | 2,394.92%257.6K | -49.03%58.02K |
| -Change in receivables | 128.87%8.82K | 399.73%12.06K | 381.00%64.26K | -201.17%-194.59K | -187.70%-137.17K | -218.43%-30.53K | 59.89%-4.02K | -213.33%-22.87K | 551.96%192.34K | 749.11%156.41K |
| -Change in prepaid assets | -42.83%4.02K | 140.45%12.09K | -339.92%-16.85K | -318.68%-762 | 283.57%15.08K | -93.07%7.03K | 72.79%-29.89K | -57.59%7.02K | 99.36%-182 | 58.83%-8.22K |
| -Change in payables and accrued expense | 114.35%11.26K | 297.87%38.31K | -3,353.38%-134.23K | 41.42%92.55K | 315.39%194.23K | -46.22%-78.43K | -112.70%-19.36K | -106.85%-3.89K | -19.34%65.44K | -178.16%-90.18K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 17.48%-271.83K | 49.31%-147.09K | -21.86%-290.55K | -84.73%-1.12M | -55.75%-260.25K | -170.22%-329.43K | -57.91%-290.16K | -79.80%-238.42K | 34.94%-605.36K | -11.10%-167.09K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -13,583.76%-95.47K | -69.30%-247.68K | -582.62%-770.55K | -64.59%-1.46M | -1,641.97%-1.2M | 100.33%708 | 65.64%-146.3K | 34.53%-112.88K | 5.12%-884.72K | 82.66%-68.75K |
| Net PPE purchase and sale | ---- | ---- | ---- | 88.03%-5.25K | ---- | ---- | ---- | ---- | -1,654.48%-43.86K | ---- |
| Net investment purchase and sale | ---- | ---- | ---- | --5.78K | ---2 | ---- | ---- | ---- | --0 | --0 |
| Net other investing changes | -1,781.08%-95.47K | -69.30%-247.68K | -582.62%-770.55K | -73.23%-1.46M | -4,690.50%-1.19M | 97.67%-5.08K | 65.64%-146.3K | 34.53%-112.88K | 9.59%-840.86K | 93.72%-24.89K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -13,583.76%-95.47K | -69.30%-247.68K | -582.62%-770.55K | -64.59%-1.46M | -1,641.97%-1.2M | 100.33%708 | 65.64%-146.3K | 34.53%-112.88K | 5.12%-884.72K | 82.66%-68.75K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -35K | -214.55%-185K | 110.50%21K | 33.33%3.56M | 1,663.06%3.6M | 0 | 550.54%161.5K | -106.82%-200K | 323.72%2.67M | -136.97%-230K |
| Net issuance payments of debt | ---35K | ---185K | --0 | 43.66%-200K | --0 | --0 | --0 | ---200K | -255.00%-355K | -130.00%-230K |
| Net common stock issuance | ---- | ---- | ---- | 21.84%3.92M | --3.92M | --0 | --0 | --0 | 329.33%3.22M | --0 |
| Proceeds from stock option exercised by employees | --0 | --0 | --21K | 15.36%161.5K | --0 | --0 | --161.5K | --0 | 1,766.67%140K | --0 |
| Net other financing activities | ---- | ---- | ---- | 2.72%-328.3K | ---- | ---- | ---- | ---- | -1,107.36%-337.49K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | ---35K | -214.55%-185K | 110.50%21K | 33.33%3.56M | 1,663.06%3.6M | --0 | 550.54%161.5K | -106.82%-200K | 323.72%2.67M | -136.97%-230K |
| Net cash flow | ||||||||||
| Beginning cash position | 40.06%659.14K | 66.17%1.24M | 75.73%2.28M | 985.81%1.3M | -91.95%141.88K | -77.62%470.6K | -72.87%745.55K | 985.81%1.3M | -91.17%119.44K | 3,889.99%1.76M |
| Current changes in cash | -22.38%-402.3K | -110.86%-579.77K | -88.66%-1.04M | -16.58%982.15K | 558.77%2.14M | 3.23%-328.72K | 57.40%-274.96K | -120.98%-551.3K | 195.46%1.18M | -718.98%-465.84K |
| End cash Position | 81.03%256.84K | 40.06%659.14K | 66.17%1.24M | 75.73%2.28M | 75.73%2.28M | -91.95%141.88K | -77.62%470.6K | -72.87%745.55K | 985.81%1.3M | 985.81%1.3M |
| Free cash from | 17.48%-271.83K | 49.31%-147.09K | -21.86%-290.55K | -73.05%-1.12M | -25.86%-265.5K | -170.22%-329.43K | -57.91%-290.16K | -79.80%-238.42K | 30.41%-649.23K | -40.26%-210.95K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.